Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

121. Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial

Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial Thurston SJ, Heeg B, de Charro F, van Hout B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of combined treatment with clopidogrel and aspirin compared with aspirin alone, for patients with ST-segment elevation myocardial infarction. The authors concluded that clopidogrel, combined with aspirin and given according to the Clopidogrel as Adjunctive Reperfusion

NHS Economic Evaluation Database.2010

122. CYP2C19 genotyping to predict response to clopidogrel

CYP2C19 genotyping to predict response to clopidogrel CYP2C19 genotyping to predict response to clopidogrel CYP2C19 genotyping to predict response to clopidogrel Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation CYP2C19 genotyping to predict response to clopidogrel. Lansdale: HAYES, Inc.. Genetic Testing Publication. 2010 Authors' objectives Dual antiplatelet (...) therapy with aspirin and a thienopyridine is recommended both in patients after acute myocardial infarction (MI) and in patients undergoing percutaneous coronary intervention (PCI) procedures with stenting. Every year in the United States, there are approximately 1.3 million inpatient PCIs and 0.9 million patients who experience an MI. Clopidogrel (trade name Plavix®; Sanofi-Aventis Inc.) is the main thienopyridine prescribed for antiplatelet therapy; in 2009, the Food and Drug Administration (FDA

Health Technology Assessment (HTA) Database.2010

123. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation National Institute for Health and Clinical Excellence. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 210. 2010 Authors' conclusions This guidance applies to people who have had an occlusive vascular event, or who have established peripheral arterial disease. For people who have had a myocardial infarction, this guidance follows on from

Health Technology Assessment (HTA) Database.2010

124. Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses

Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults (...) M. Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Technology report no 131. 2010 Authors' conclusions The estimates of relative effectiveness for clopidogrel and ticlopidine with ASA suggest that the optimal therapeutic choice is unclear. Clopidogrel and ticlopidine are at least

Health Technology Assessment (HTA) Database.2010

125. Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses

Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events (...) . Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults with acute coronary syndrome or peripheral vascular disease: clinical and cost-effectiveness analyses. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Technology report no. 133. 2010 Authors' conclusions In patients with ACS without ST-segment elevation, therapy with clopidogrel and ASA was more efficacious than ASA alone, with an increased risk of major bleeding. A post hoc analysis

Health Technology Assessment (HTA) Database.2010

126. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel

Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel Kwok CS, Loke YK CRD summary This review found conflicting and inconsistent data on the adverse interaction between (...) clopidogrel and proton-pump inhibitors. The authors' conclusions agreed with the results of their review and appear to be appropriate. Authors' objectives To evaluate cardiovascular outcomes and mortality in patients taking clopidogrel with versus without concomitant proton-pump inhibitors. Searching MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched in October 2009, without language restrictions. The search terms were reported and a PubMed alert was set up

DARE.2010

127. Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis

Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF CRD summary The review concluded that among people who underwent percutaneous coronary intervention and were treated with clopidogrel, non-responders (...) to clopidogrel were at increased risk of cardiovascular events compared to those who had a good response to antiplatelets. As data came from observational studies whose quality assessment was not reported, the conclusions should be treated with some caution. Authors' objectives To assess the evidence on the relationship between clopidogrel non-responsiveness and clinical outcomes in people with coronary artery disease undergoing percutaneous coronary intervention (PCI). Searching MEDLINE (1966 to January

DARE.2010

128. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. 20979470 2010 10 28 2010 11 05 2016 11 25 1533-4406 363 18 2010 Oct 28 The New England journal of medicine N. Engl. J. Med. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. 1704-14 10.1056/NEJMoa1008410 It has been suggested that clopidogrel may be less effective in reducing the rate of cardiovascular events among persons who are carriers of loss-of-function CYP2C19 alleles that are associated with reduced (...) conversion of clopidogrel to its active metabolite. We genotyped patients from two large, randomized trials that showed that clopidogrel, as compared with placebo, reduced the rate of cardiovascular events (the primary efficacy outcome) among patients with acute coronary syndromes and among patients with atrial fibrillation. Patients were genotyped for three single-nucleotide polymorphisms (*2, *3, *17) that define the major CYP2C19 alleles. Among 5059 genotyped patients with acute coronary syndromes

NEJM2010

129. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. 20817281 2010 10 11 2010 10 27 2015 06 16 1474-547X 376 9748 2010 Oct 09 Lancet (London, England) Lancet Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (...) (CURRENT-OASIS 7): a randomised factorial trial. 1233-43 10.1016/S0140-6736(10)61088-4 Clopidogrel and aspirin are the most commonly used antiplatelet therapies for percutaneous coronary intervention (PCI). We assessed the effect of various clopidogrel and aspirin regimens in prevention of major cardiovascular events and stent thrombosis in patients undergoing PCI. The CURRENT-OASIS 7 trial was undertaken in 597 centres in 39 countries. 25,086 individuals with acute coronary syndromes and intended

Lancet2010

130. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. 20818903 2010 09 07 2010 09 16 2013 11 21 1533-4406 363 10 2010 Sep 02 The New England journal of medicine N. Engl. J. Med. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. 930-42 10.1056/NEJMoa0909475 Clopidogrel and aspirin are widely used for patients with acute coronary syndromes and those undergoing percutaneous coronary intervention (PCI). However, evidence-based guidelines for dosing have (...) not been established for either agent. We randomly assigned, in a 2-by-2 factorial design, 25,086 patients with an acute coronary syndrome who were referred for an invasive strategy to either double-dose clopidogrel (a 600-mg loading dose on day 1, followed by 150 mg daily for 6 days and 75 mg daily thereafter) or standard-dose clopidogrel (a 300-mg loading dose and 75 mg daily thereafter) and either higher-dose aspirin (300 to 325 mg daily) or lower-dose aspirin (75 to 100 mg daily). The primary

NEJM2010

131. Clopidogrel with or without omeprazole in coronary artery disease.

Clopidogrel with or without omeprazole in coronary artery disease. 20925534 2010 11 11 2010 11 30 2013 11 21 1533-4406 363 20 2010 Nov 11 The New England journal of medicine N. Engl. J. Med. Clopidogrel with or without omeprazole in coronary artery disease. 1909-17 10.1056/NEJMoa1007964 Gastrointestinal complications are an important problem of antithrombotic therapy. Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved (...) this in patients receiving dual antiplatelet therapy. Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel. We randomly assigned patients with an indication for dual antiplatelet therapy to receive clopidogrel in combination with either omeprazole or placebo, in addition to aspirin. The primary gastrointestinal end point was a composite of overt or occult bleeding, symptomatic gastroduodenal ulcers or erosions, obstruction, or perforation. The primary

NEJM2010

132. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. 20079528 2010 01 29 2010 02 17 2015 06 16 1474-547X 375 9711 2010 Jan 23 Lancet (London, England) Lancet Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. 283-93 10.1016/S0140-6736(09)62191-7 Variation in and irreversibility (...) of platelet inhibition with clopidogrel has led to controversy about its optimum dose and timing of administration in patients with acute coronary syndromes. We compared ticagrelor, a more potent reversible P2Y12 inhibitor with clopidogrel in such patients. At randomisation, an invasive strategy was planned for 13 408 (72.0%) of 18 624 patients hospitalised for acute coronary syndromes (with or without ST elevation). In a double-blind, double-dummy study, patients were randomly assigned in a one-to-one

Lancet2010

134. Clopidogrel and proton pump inhibitors: interaction?updated advice

Clopidogrel and proton pump inhibitors: interaction?updated advice Clopidogrel and proton pump inhibitors: interaction—updated advice Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Clopidogrel and proton pump inhibitors: interaction—updated advice From: Published: 1 April 2010 Therapeutic area: and In light of the most recent evidence, the previous advice on the concomitant use of clopidogrel with proton pump inhibitors has now been modified. Use of either (...) omeprazole or esomeprazole with clopidogrel should be discouraged. The current evidence does not support extending this advice to other PPIs Article date: April 2010 Clopidogrel is indicated for the prevention of atherothrombotic events in patients who have had a myocardial infarction or ischaemic stroke, or who have established peripheral arterial disease. Combined with aspirin, the brand leader product (Plavix) may also be used to prevent atherothrombotic events in patients with acute coronary syndrome

MHRA Drug Safety Update2010

135. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)

Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80) Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome | Guidance and guidelines | NICE Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome Technology appraisal guidance [TA80] Published date: 28 July 2004 Guidance (published in March 2010). Recommendation 1.3 has been updated and replaced by recommendation 1.3.18 in (published in November 2013). Explore

National Institute for Health and Clinical Excellence - Technology Appraisals2010

136. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210) Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events | Guidance and guidelines | NICE Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events Technology appraisal guidance [TA210] Published date: 15 December 2010 Share Guidance on clopidogrel (Plavix) and modified-release dipyridamole (Persantin Retard and Asasantin (...) Retard) for preventing occlusive vascular events in adults. This guidance replaces NICE technology appraisal guidance on clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (TA90). Guidance development process Is this guidance up to date? . We found nothing new that affects the recommendations in this guidance. Next review : This guidance will be reviewed if there is new evidence that is likely to affect the recommendations. Your responsibility

National Institute for Health and Clinical Excellence - Technology Appraisals2010

137. DuoCover - clopidogrel / acetylsalicylic acid

DuoCover - clopidogrel / acetylsalicylic acid European Medicines Agency 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: mail@ema.europa.eu http://www.ema.europa.eu London, 17 December 2009 Doc. Ref: EMA/CHMP/195986/2010 CHMP ASSESSMENT REPORT FOR DuoCover International Nonproprietary Name: clopidogrel / acetylsalicylic acid Procedure No. EMEA/H/C/001144 TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE 3 1.1 Submission (...) indication: DuoCover is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoCover is a fixed-dose combination product for continuation of therapy in: ? Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention ? ST segment elevation acute myocardial infarction in medically treated

European Medicines Agency - EPARs2010

138. DuoPlavin - clopidogrel / acetylsalicylic acid

DuoPlavin - clopidogrel / acetylsalicylic acid European Medicines Agency 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 13 E-mail: mail@ema.europa.eu http://www.ema.europa.eu London, 17 December 2009 Doc. Ref: EMA/CHMP/196090/2010 CHMP ASSESSMENT REPORT FOR DuoPlavin International Nonproprietary Name: clopidogrel / acetylsalicylic acid Procedure No. EMEA/H/C/001143 TABLE OF CONTENTS 1. BACKGROUND INFORMATION ON THE PROCEDURE 3 1.1 Submission (...) for the following indication: DuoPlavin is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). DuoPlavin is a fixed-dose combination product for continuation of therapy in: ? Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention ? ST segment elevation acute myocardial infarction

European Medicines Agency - EPARs2010

139. The Safety and Efficacy of Clopidogrel in Children with Heart Disease: A Systematic Review

The Safety and Efficacy of Clopidogrel in Children with Heart Disease: A Systematic Review "The Safety and Efficacy of Clopidogrel in Children with Heart Disease:" by Kristen Schmiedeskamp < > > > > > Title Author Date of Award 12-2010 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Robert P. Rosenow, Pharm.D., O.D. Rights . Abstract Background: Clopidogrel, an oral antiplatelet, has been used off-label in pediatric patients at risk (...) for thrombosis, including those with heart disease, for more than a decade. While numerous clinical trials in adults have resulted in the formation of comprehensive management guidelines, considerably less is known about the safety and efficacy of clopidogrel use in children. Method: An exhaustive literature search was performed using PubMed, Web of Science, Cochrane, Medline, CINAHL and International Pharmaceutical Abstracts. The keywords searched included “clopidogrel”, “child”, “teen”, “young”, “pediatric

Pacific University EBM Capstone Project2010

140. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty

Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty 19796737 2009 10 02 2009 10 29 2017 02 03 1558-3597 54 15 2009 Oct 06 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute (...) myocardial infarction) trial. 1438-46 10.1016/j.jacc.2009.06.021 Our aim was to determine whether a 600-mg loading dose of clopidogrel compared with 300 mg results in improved clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). A 600-mg loading dose of clopidogrel compared with 300 mg provides more rapid and potent inhibition of platelet activation. In the HORIZONS-AMI (Harmonizing Outcomes With Revascularization

EvidenceUpdates2009